Fluoxetine inhibits matrix metalloprotease activation and prevents disruption of blood–spinal cord barrier after spinal cord injury
Authors:
Open Access
- 13 July 2012
- journal article
- research article
- Published by Oxford University Press (OUP) in Brain
- Vol. 135 (8) , 2375-2389
Abstract
After spinal cord injury, the disruption of blood–spinal cord barrier by activation of matrix metalloprotease is a critical event leading to infiltration of blood cells, inflammatory responses and neuronal cell death, contributing to permanent neurological disability. Recent evidence indicates that fluoxetine, an anti-depressant drug, is shown to have neuroprotective effects in ischaemic brain injury, but the precise mechanism underlying its protective effects is largely unknown. Here, we show that fluoxetine prevented blood–spinal cord barrier disruption via inhibition of matrix metalloprotease activation after spinal cord injury. After a moderate contusion injury at the T9 level of spinal cord with an infinite horizon impactor in the mouse, fluoxetine (10 mg/kg) was injected intraperitoneally and further administered once a day for indicated time points. Fluoxetine treatment significantly inhibited messenger RNA expression of matrix metalloprotease 2, 9 and 12 after spinal cord injury. By zymography and fluorimetric enzyme activity assay, fluoxetine also significantly reduced matrix metalloprotease 2 and matrix metalloprotease 9 activities after injury. In addition, fluoxetine inhibited nuclear factor kappa B-dependent matrix metalloprotease 9 expression in bEnd.3, a brain endothelial cell line, after oxygen–glucose deprivation/reoxygenation. Fluoxetine also attenuated the loss of tight junction molecules such as zona occludens 1 and occludin after injury in vivo as well as in bEnd.3 cultures. By immunofluorescence staining, fluoxetine prevented the breakdown of the tight junction integrity in endothelial cells of blood vessel after injury. Furthermore, fluoxetine inhibited the messenger RNA expression of chemokines such as Groα, MIP1α and 1β, and prevented the infiltration of neutrophils and macrophages, and reduced the expression of inflammatory mediators after injury. Finally, fluoxetine attenuated apoptotic cell death and improved locomotor function after injury. Thus, our results indicate that fluoxetine improved functional recovery in part by inhibiting matrix metalloprotease activation and preventing blood–spinal cord barrier disruption after spinal cord injury. Furthermore, our study suggests that fluoxetine may represent a potential therapeutic agent for preserving blood–brain barrier integrity following ischaemic brain injury and spinal cord injury in humans.Keywords
This publication has 81 references indexed in Scilit:
- Remote Exosites of the Catalytic Domain of Matrix Metalloproteinase-12 Enhance Elastin DegradationBiochemistry, 2011
- Brief Suppression of Abcc8 Prevents Autodestruction of Spinal Cord After TraumaScience Translational Medicine, 2010
- Matrix Metalloproteinase-9 Mediates Hypoxia-Induced Vascular Leakage in the Brain via Tight Junction RearrangementJournal of Cerebral Blood Flow & Metabolism, 2009
- De novo expression of Trpm4 initiates secondary hemorrhage in spinal cord injuryNature Medicine, 2009
- Normobaric hyperoxia attenuates early blood–brain barrier disruption by inhibiting MMP‐9‐mediated occludin degradation in focal cerebral ischemiaJournal of Neurochemistry, 2009
- Induction of MMP-9 Expression and Endothelial Injury by Oxidative Stress after Spinal Cord InjuryJournal of Neurotrauma, 2008
- Griffonia simplicifolia isolectin B4 identifies a specific subpopulation of angiogenic blood vessels following contusive spinal cord injury in the adult mouseJournal of Comparative Neurology, 2007
- Endothelial sulfonylurea receptor 1–regulated NCCa-ATP channels mediate progressive hemorrhagic necrosis following spinal cord injuryJournal of Clinical Investigation, 2007
- Anti-inflammatory properties of desipramine and fluoxetineRespiratory Research, 2007
- Dystroglycan is selectively cleaved at the parenchymal basement membrane at sites of leukocyte extravasation in experimental autoimmune encephalomyelitisJournal of Experimental Medicine, 2006